Solid Biosciences Inc. announced it granted 6,580 restricted stock units (RSUs) to a newly hired employee as an inducement to join the company. The RSUs will vest in four equal annual installments, contingent on continued employment. This grant follows the company’s 2024 Inducement Stock Incentive Plan and complies with Nasdaq Listing Rule 5635(c)(4). Solid Biosciences focuses on developing gene therapies for rare neuromuscular and cardiac diseases, advancing treatments like SGT-003 for Duchenne muscular dystrophy. This equity grant aims to attract talent to support its innovative genetic medicine pipeline.
The phase III ENDURANCE trial showed that two years of lenalidomide maintenance therapy offers the same long-term survival benefit as indefinite treatment for patients with standard-risk multiple myeloma who are not transplant candidates. After nearl...
Lowey Dannenberg, P.C. is investigating Hims & Hers Health, Inc. for allegedly sharing sensitive user health data, including medical histories and mental health info, with third parties without proper consent. This raises concerns about violations of...
Digital agency 9thCO completed a major digital transformation for DNRS, moving from a fragmented WordPress setup to a unified composable architecture. This upgrade centralizes user management, integrates key business tools like CRM and scheduling, an...
Citigroup downgraded Apollo Global Management's stock from Buy to Reduce due to concerns over a potential economic slowdown and a sharp drop in U.S. private credit lending. Apollo's shares are trading well below their 52-week high, reflecting caution...
Conagra Brands reported its Q2 earnings with an EPS of $0.47, slightly beating estimates but down from last year. Revenue missed expectations at $2.88 billion, and the company announced a loss and a significant dividend cut as part of a new conservat...
